Cardiol Therapeutics (CRDL) Corporate presentation summary

Pipeline and clinical programs

• Advancing CardiolRx, an oral cannabidiol formulation, in Phase III for recurrent pericarditis and completed Phase II for acute myocarditis; developing CRD-38, a subcutaneous candidate, for heart failure in IND-enabling studies.

• CardiolRx targets inflammasome pathway activation, aiming to reduce inflammation and fibrosis in heart diseases.

• MAVERIC Phase III trial for recurrent pericarditis is over 50% enrolled, targeting 100% enrollment by Q2 2026.

• ARCHER Phase II trial in acute myocarditis showed significant structural cardiac improvements and safety.

• CRD-38 preclinical data indicate prevention of inflammation, fibrosis, and cardiac dysfunction in heart failure models.

Clinical results and efficacy

• MAVERIC Phase II showed rapid, durable reduction in pericarditis pain and inflammation, with 71% of patients experiencing no recurrence during the extension period.

• CardiolRx demonstrated a significant reduction in C-reactive protein and pericarditis events per year.

• ARCHER Phase II demonstrated significant reduction in left ventricular mass and trends toward reduced extracellular and intracellular volumes, comparable to leading heart failure therapies.

• CardiolRx was safe and well tolerated in both pericarditis and myocarditis trials.

Market opportunity and positioning

• CardiolRx addresses a >$1B market in recurrent pericarditis, targeting ~40,000 patients in the US, with potential as a second-line therapy before corticosteroids or IL-1 blockers.

• Heart failure represents a multi-billion-dollar market with high unmet need, especially for therapies targeting inflammation and fibrosis.

• No approved drugs currently target inflammatory/fibrotic mechanisms in heart failure.